Power Law company profile

NGM Biopharmaceuticals

Biotech & Life Sciences · South San Francisco, United States · Founded 2007 · IPO 2019 Thoroughbred

A clinical-stage biopharmaceutical company which engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases

Revenue

$4.4M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

8 investors on NGM Biopharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage

The Column Group

Rho Ventures

Prospect Venture Partners

Series B+ 5 investors entered at this stage

TopSpin Marketing Group

Inc.

Rho Capital Partners

Solon Mack Capital

Merck & Co.

Global footprint

Where NGM Biopharmaceuticals has talent and traffic

AI talent share

2.5% of workforce is AI talent
(2 of 81 staff)

Core AI00%

Other AI22.47%

Non-AI workforce7997.53%

Workforce by country

2 countries with
team presence

🇺🇸 United States98.8%

🇵🇰 Pakistan1.2%

2 countries shown

Web traffic by country

5.1K monthly visits
across markets

🇺🇸 United States90.2%

🇦🇺 Australia7.8%

Top 2 markets shown

Market sentiment

What the market is saying about NGM Biopharmaceuticals

An AI-synthesized read of the highest-engagement posts about NGM Biopharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NGM Biopharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles